General Information from Answers.com
Definition
Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin’s lymphoma characterized under the microscope by expansion of the mantle zone area of the lymph node with a homogeneous (structurally similar) population of malignant small lymphoid cells. These cancerous cells have slightly irregular nuclei and very little cytoplasm, and are mixed with newly made normal lymphocytes (white blood cells) that travel from the bone marrow to the lymph nodes and spleen. Unlike normal lymphocytes, they do not mature properly and become cancerous instead.
Description
The body’s immune system produces two types of lymphocytes or white blood cells: the B cells which are made in the bone marrow and the T cells which are made in the thymus. Both types of cells are found in the lymph, the clear liquid that bathes tissues and circulates in the lymphatic system. Lymphomas are cancers that occur in this lymphatic system and B-Cell lymphomas—also called non-Hodgkin’s lymphomas—include follicular lymphomas, small non-cleaved cell lymphomas (Burkitt’s lymphomas), marginal zone lymphomas (MALT lymphomas), small lymphocytic lymphomas, large cell lymphomas and also mantle cell lymphomas.
Mantle cell lymphoma accounts for 5% to 10% of all lymphomas diagnosed and 5% of B-cell lymphomas. There are three subsets of MCL cells: the mantle zone type, the nodular type, and the blastic or blastoid (immature) type. These various types often occur together to some degree, and approximately 30% to 40% of diagnoses are of mixed mantle and nodular type. As MCL develops further, the non-cancerous mantle centers also become invaded by cancerous cells. In about 20% of these cases, the cells become larger, and of the blastic type.
Extensive debates are ongoing concerning the grade of this cancer. European classification used to classify it as a low-grade cancer because it is initially slow-growing, while American classification considered it intermediate based on patients’ shorter average survival rate. The combined European-American classification (REAL), is still discussing the status of mantle cell lymphoma. This is due to the mixed nature of MCL cells. Blastic type-MCL seems to be considered as a high-grade cancer because it spreads at about the rate of other lymphomas belonging to that category. The studies currently attempting to describe the precise nature of these cells will be key to any general agreement that is finally reached.
Demographics
Mantle cell lymphoma is rare in persons under the age of 50. It is most often seen in men aged 50–70 years. Out of 1,000 persons diagnosed with MCL, approximately 33% will be women. This cancer has the shortest average survival of all lymphoma types.
Causes and Symptoms
The cause of MCL is unknown. Many of its symptoms are shared by other lymphomas as well and patients generally complain of fatigue, anemia, low grade fevers, night sweats, weight loss, rashes, digestive disturbances, chronic sinus irritation, recurrent infections, sore throat, shortness of breath, muscle and bone aches and edema.
More specific symptoms include spleen enlargement (in about 60% to 80% of cases), particularly with nodular-type MCL. Swollen lymph nodes are an early-stage symptom, even though the general health of the patient is good. Mild anemia is also common. Some patients also report lower back pain, and burning pain in the legs and testicles. As MCL becomes more advanced, the lymph nodes increase in volume, and the general symptoms become more pronounced.
In the end stage of MCL, neurologic symptoms appear, indicating that the MCL has spread to the central nervous system.
Diagnosis
MCL is very similar to several other lymphoma types and special care must be taken with the diagnosis. It should not be made from blood or bone marrow specimens alone. It is believed that immunologis tests are required to make the correct diagnosis. Immunophenotyping is one such test, it is used to determine what kind of surface molecules are present on cells, and thus, the exact type of lymphoma from a tissue sample. The Lymphoma Research Foundation of America recommends that several opinions be sought from recognized mantle cell experts to confirm the accuracy of the diagnosis.
At the time of diagnosis, mantle cell lymphoma has usually spread into other tissues such as the lymph nodes, spleen, bone marrow (up to 90% of cases), or to Waldeyer’s ring (the ring of adenoid, palantine and lingual tonsils at the back of the mouth) or to the gastrointestinal tract. MCL can also spread to the colon, in which case it is diagnosed as multiple lymphomatous polyposis.
Treatment Team
Depending on the type of MCL and stage of the cancer, the treatment team may include a radiation oncologist, a medical oncologist, a surgeon and a neurologist.
Clinical Staging, Treatments, and Prognosis
There is no formal staging system for mantle cell lymphoma and no standard treatment has yet been adopted for MCL patients. Patients have been treated with surgery, radiation, single drug or combination chemotherapy and stem cell transplants. CHOP is one of the most common chemotherapy regimens for treating MCL. It derives its name from the combination of drugs used: Cyclophophamide (cytoxan, neosar), adriamycin (docorubicin or Hydroxydoxorubicin), vincristine (Oncovin), and Prednisone.
There is no cure for mantle cell lymphoma. As with other slow-growing lymphomas, spontaneous remissions have been reported, but only partial, lasting a year at the most. All mantle cell lymphoma experts agree that the long-term prognosis of MCL patients receiving conventional treatment is poor, and that there is an urgent need for new, improved therapies.
Alternative and Complementary Therapies
Because MCL is a cancer of the lymphatic system, immunologic therapies are often used, or combined with the more conventional radiation and chemotherapy treatments. Immunological therapies take advantage of the body’s immune system. The immune system is a network of specialized cells and organs that defends the body against foreign invaders (antigens) by producing special “defense” proteins, an example of which are the antibodies. These substances recognize and attach to the antigens, usually found on the surface of cells and destroy them. There are reports of immunological therapies being used for MCL using interferon, one such natural substance produced by the body in response to a virus. Numerous studies show that interferons can stimulate the immune system to fight the growth of cancer, but there has not yet been enough evidence produced to see it emerge as a strong candidate for MCL treatment.
Other immunological therapies based on monoclonal antibodies (MABs or MOABs) have recently emerged, such as Rituxan (ritucimab). MABs work on cancer cells in the same way natural antibodies work, by identifying and binding to the target cells, alerting other cells in the immune system to the presence of the cancer cells. MABs are very specific for a particular antigen, meaning that one designed for a B-cell lymphoma will not work on T-cell lymphomas. MABs used alone may enhance a patient’s immune response to the cancer but they are thought to be more efficient when combined to another form of therapy, such as a chemotherapeutic drug. This way, the cancer is attacked on two fronts: chemical attack from the chemotherapy and immune response attack stimulated by the MAB.
Coping With Cancer Treatment
It is important to have a caregiver system when receiving medical treatment for MCL, and it is just as important to have a network of support for coping with the non-medical aspects of the cancer. Friends, relatives, coworkers and health professionals all can provide help, as well as the national cancer associations, some specifically addressing the needs of lymphoma patients. Please refer to the Resources section at the end of this entry for contact information.
Clinical Trials
Clinical trials addressing the needs of MCL patients are very recent because the mantle cell lymphoma subtype has only recently been defined. There are now several trials being carried out in the United States specifically for mantle cell. Some other trials designed for patients with lymphomas may also accept mantle cell patients. Ongoing trials in this area are cheifly concerned with investigating monoclonal antibodies. Information regarding clinical trials can be obtained through the Clinical Trials web site listed at the end of this entry.
The following clinical protocols are specifically designed for MCL patients:
- The MD Anderson Protocol (high-dose chemotherapy with or without stem cell transplant)
- Rituxan, by itself or with CHOP
- Bexxar
- Oncolym
- Flavopiridol
- Phenylacetate
The MD Anderson Protocol is high dose chemotherapy with or without stem cell transplant. It is available at MD Anderson Cancer Center in Texas. The regimen consists of the following sequence: HyperCVAD (Cytoxan, Vincristine, Adriamycin and Decadron) with high dose ARA-C and methotrexate. If well tolerated, and in younger patients, it is then followed by high dose cyclophosphamide, total body irradiation and stem cell transplant. Each one of these two cycles is delivered four times, so it is an eight month commitment. This is a trial that has the patient community very interested, and their results so far have been encouraging. However, until a comparison study is run, it will not be known if the results are truly an improvement. Dr Roda the MCL list remarked: “Until MD Anderson’s data cover five year survival and are reproduced elsewhere, their approach must be considered experimental. Without being critical of any one center, it’s well recognized that many pilot programs at major centers don’t turn out as good when larger comparative studies are performed. Thus, I would encourage patients to participate in research trials, particularly innovative trials including stem cell or conventional chemo plus Rituxan, interferon, etc. But I can’t say that any one approach should be standard of care until randomized trials are completed.” A similar protocol is followed by Dr Julie Vose at Nebraska, with good results. Also, the MD Anderson doctors will help local oncologists implement the protocol if a patient selects it — the patient need not be part of the trial to obtain this treatment.
Rituxan is a cold monoclonal antibody that was approved in 1997. It can be administered by any oncologist locally. It is approved for low grade relapsed NHL, but is widely used off label. It is given in 4-8 infusions at weekly intervals. The drug has low toxicity and is very well tolerated by most patients. Usually, however, the regression effected by Rituxan is not long lasting (about 8 mos. in low grade relapsed NHL). For that reason, trials are underway in combination with CHOP. Excellent response rates have been reported for this combination, with CR reported in the patient community to be as high as 80%. Dr Orion Howard at Dana Farber is running the trial for MCL.
Bexxar is a radiolabeled monoclonal antibody, coupled with radioactive iodine. Dr Kaminski at the U of Wisconsin has been running trials with low radioactive Bexxar, but they have had no luck with MCL. The word is that they treated 5 patients with MCL and they only obtained a partial response in three patients, of a very brief duration (3 months). They are not accepting MCL patients into the current trial for previously untreated patients. Dr Press in Washington state has been using high radioactive Bexxar with high dose chemotherapy followed by stem cell rescue. He has reported 74% of patients progression-free after a year and a half.
Oncolym is another iodine radiolabeled antibody. Trials for relapsed intermediate lymphomas are being run at many cancer centers around the country (MD Anderson, U of New Mexico, George Washington U, Sylvester Cancer Center in Miami, Iowa City VA, U of Illinois in Chicago).
LL2 is yet another antibody, available in both cold and radiolabeled versions, effective against CD22 antigen. Trials for relapsed intermediate NHL are being run at Sloan Kettering, Buffalo, U of Nebraska, and Garden State Cancer Center in NJ.
Flavopiridol is a drug that was thought to have a particular promise against MCL, and may still find its niche. Flavopiridol is reported to induce apoptosis of normal lymphoid cells, causes immunosuppression, and has shown antitumor activity. It is active against cyclin D, and in mice with transplanted lymphoma tumors, this drug was very effective. There are recently started trials at Dana Farber and Chicago. Unfortunately, the first 3 patients in Chicago failed to respond.
Phenylacetate is being tested at Mayo. This is a low toxicity treatment based on the ideas of the alternative cancer researcher Dr Burzynski. It is a peptide that depletes a certain amino acid. One disadvantage of the treatment is a temporary unpleasant body odor the drug causes. The Mayo clinic has not publicly disclosed any results yet though the trial has been going on for 2-3 years now. They will disclose information to patients seriously interested in joining the trial.
Purine analogs (fludarabine and cladribine) have not shown good results with MCL though several trials remain open and a new one is planned. Some of the trials use the analogs with other drugs, for example interferon and cyclophosphamide. According to a report by Lawrence Piro, M.D. of Cedars Sinai Medical Center that he presented at the Pan Pacific Lymphoma Conference, “fifteen patients with mantle cell lymphoma were treated with Fludarabine achieving an overall remission rate of 27% with one complete remission and three partial remissions reported. Dr Weisenburger, a noted expert, has recently written: “Therapeutic experience with the purine analogues, fludarabine and 2-CDA, and interferon has been disappointing.” I was puzzled why trials for a treatment with disappointing results are continued. Dr Roda on the mantle cell list furnished the following explanation: “1. The trial could be for patients with refractory disease (ie failed adriamycin containing therapy and are not a candidate for anything else). 2. There is data suggesting that purine analogues might be additive to adriamycin and/or alkylating agents. These trials would still be legitimate. 3. While I personally don’t think that purine analogues are very helpful in MCL, I don’t know this for a medical fact. Thus while I wouldn’t use fludarabine or cladribine as a single agent in this disease, a trial that was started (a few years ago) and has yet to include enough patients to have a statistically meaningful result should be continued. Once an older trial has reached enough patients to show a statistical benefit to any arm, the trial is usually stopped.”
Prevention
Because the cause of MCL is unknown, no prevention measures can be recommended.
Special Concerns
Special concerns that apply to lymphoma patients may also apply to MCL patients. Because MCL is a cancer that usually involves chemotherapy and radiation therapy, it can be severely damaging to organ function and long-term resistance. In addition to the immediate side effects of these treatments, other effects appear after treatment is completed, one of which, called Post-Cancer Fatigue (PCF), is often seen with lymphoma patients. This is fatigue that persists after treatment and can sometimes be extreme. The medical team will be able to offer the best advice to deal with PCF.
Resources
Periodicals
Grosfeld, J. L. “Risk-based Management of Solid Tumors in Children.” American Journal of Surgery 180 (November 2000): 322–7.
Organizations
The Leukemia and Lymphoma Society. 1311 Mamaroneck Ave. White Plains, N.Y., 10605. (914) 949-5213. [cited July 5, 2005]. .
The Lymphoma Research Foundation of America 8800 Venice Blvd., Suite 207, Los Angeles, CA 90034. (310) 204-7040. [cited July 5, 2005]. .
Other
Lymphoma Information Network Website. 7 June 2001. [cited July 5, 2005]. .
National Institutes of Health Clinical Trials. [cited July 5, 2005]. .
Oregon Health and Science University, Cliniweb International Page on B-cell Lymphomas. [cited July 5, 2001].
—Monique Laberge, Ph.D.
From Wikipedia, the free encyclopediaMantle cell lymphoma (MCL) is one of the rarer of the non-Hodgkin’s lymphomas, comprising about 6% of NHL cases. There are only about 15,000 patients presently in the U.S. (The prevalence seems to be somewhat higher in Europe.) While it is difficult to treat and seldom considered cured, investigations into better treatments are actively pursued world-wide. Median survival times were about 3 years, but are now estimated as approaching 6 years for new patients.
MCL is a subtype of B-cell lymphoma, due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles. MCL cells generally over-express cyclin D1 due to a t(11:14) chromosomal translocation in the DNA. The cause is unknown and not genetic. MCL is not communicable. It essentially is an abnormal break and subsequent translocation in a gene that causes the cells to divide too early before becoming capable of helping to fight diseases. In addition, the cells do not die as they should and therefore accumulate in the lymphoid system, including lymph nodes and the spleen, with non-useful cells eventually rendering the system dysfunctional. MCL affected cells proliferate in a nodular or diffuse pattern with two main cytologic variants: typical or blastic. Typical cases are small to intermediate sized cells with irregular nuclei. Blastic (aka blastoid) variants have intermediate to large sized cells with finely dispersed chromatin and are more aggressive in nature
Mantle Cell Lymphoma – Leukemia & Lymphoma Society Adobe Acrobat (pdf format) paper on Mantle Cell Lymphoma.
In the News
Aggressive Non-Hodgkin’s Lymphoma (Mantle Cell Lymphoma) On The Rise – ScienceDaily (2008-07-07): A new study indicates that the incidence of mantle cell lymphoma, an aggressive type of non-Hodgkin’s lymphoma, is on the rise, most frequently striking men, Caucasians and older individuals.
This page has the following sub pages.
